12 results
1. Measure DNIC and offset analgesia in neuropathic pain patients;2. Compare DNIC and offset analgesia in chronic pain patients with DNIC and offset analgesia in healthy volunteers;3. Assess the effect of oral tapentadol on DNIC and offset analgesia…
The objectives are:1. Compare how the body processes single and multiple doses of tapentadol for a certain period after taking the tablets. This way absorption, excretion and distribution of the drug in the body is assessed.2. Findings of the safety…
The objective of this study is to investigate the extent of respiratory depression at equi-analgesic dosages of tapentadol and oxycodone
(1) To phenotype chronic low back pain patients in terms of endogenous modulation of pain, central sensitization/facilitation, and the presence of a neuropathic pain component;(2) To assess the effect of a three-month treatment with tapentadol on…
(1) To phenotype fibromyalgia patients in terms of endogenous modulation of pain, central sensitization/facilitation, the presence of a neuropathic pain component and small fiber neuropathy;(2) To assess the effect of a three-month treatment with…
The main objective is to determine the change in CS parameters upon administration of tapentadol in comparison to pregabalin in patients suffering from chronic pain that has a visceral or deep somatic origin.
To construct the utility surfaces of tapentadol and oxycodone.
The purpose of this study is to investigate how quickly and to what extent two 25 mg prolonged release tapentadol tablets are absorbed and eliminated from the body (this is called pharmacokinetics) when compared to one 50 mg prolonged release…
To prevent the development of chronic postoperative pain after inguinal hernia surgery and knee replacement surgery and to to further explore the mechanism behind the development of chronic postoperative pain.
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab in…
Primary- Part 1: To identify recommended Phase 2 doses and schedules (RP2Ds) for each combination.- Part 2: To characterize the safety of each RP2D for each combinationSecondary- To characterize the pharmacokinetics and pharmacodynamics of each…
The primary objective of the study is to compare the PFS of SPd versus EloPd in patients with MM who have received 1 to 4 prior anti-MM lines of therapy and never received pomalidomide, selinexor, or elotuzumab. Patients must have had prior…